Table 5. Excess relative risks (ERRs) of CNS tumour, leukaemia, and lymphoma related to cumulative organ doses in mGy, adjusted or not for the presence of PFs for cancer for the primary and secondary end points.
|
CNS cancer |
Leukaemia |
Lymphoma |
||||
|---|---|---|---|---|---|---|
| ERR | (95% CI) | ERR | (95% CI) | ERR | (95% CI) | |
|
Primary end point (2-year exclusion period) | ||||||
| Not adjusted for any PF | 0.022 | (−0.016; 0.061) | 0.057 | (−0.079; 0.193) | 0.018 | (−0.068; 0.104) |
| Adjusted for all specific PF | 0.012 | (−0.013; 0.037) | 0.047 | (−0.065; 0.159) | 0.008 | (−0.057; 0.073) |
| Adjusted for one specific PF | ||||||
| NF1, NF2 | 0.019 | (−0.016; 0.053) | NA | NA | ||
| Other phacomatoses | 0.014 | (−0.015; 0.042) | NA | NA | ||
| Retinocytoma | 0.020 | (−0.016; 0.057) | NA | NA | ||
| Down syndrome | NA | 0.068 | (−0.087; 0.222) | NC | ||
| CVID, SVID | NA | 0.054 | (−0.076; 0.184) | NC | ||
| Transplantation | NA | 0.045 | (−0.065; 0.155) | 0.008 | (−0.057; 0.073) | |
| Ataxia telangiectasia | NA | NA | −0.010 | (−0.035; 0.014) | ||
|
Secondary end point | ||||||
| Not adjusted for any PF | 0.015 | (−0.022; 0.052) | Not available | Not available | ||
| Adjusted for all specific PF | 0.007 | (−0.017; 0.032) | ||||
Abbreviations: 95% CI=Wald-based 95% confidence intervals; CNS=central nervous system; CVID=common variable immune deficiency; NA=not applicable (the disease does not particularly predispose the affected individuals to cancer at that site); NC=not computed (no cancer was diagnosed in patients with that PF); NF1, NF2=neurofibromatosis type 1, type 2; PF=factors predisposing specifically to cancer at that site; SVID=severe combined immune deficiency.
ERRs are estimated by Poisson models (maximum likelihood estimates) adjusted for gender, period of birth (1995–2001, 2002–2010), attained age (in years), time since entry into the cohort (in years), as well as the presence of PF (yes/no), unless stated otherwise. No sufficient cases allowed providing risk estimates for other predisposing factors considered in the study. For the primary end points, the results are given for a 2-year exclusion period; for the secondary end point, the exclusion period is 1 year. The analysis for the secondary end point is performed from 296 831 persons-years and 21 cases of CNS tumours (one case with a missing time to diagnosis was removed).